Yuping Ning
Clinical Researcher in Psychiatry
Papers
Trials
Key Impact
Notable for leading and co‑authoring multiple clinical trials and comparative studies of repeated ketamine/esketamine infusions for difficult‑to‑treat depressive states, including adolescent suicidal ideation and anhedonia.
Background & Research
Yuping Ning (often cited as Y‑P Ning) is a clinical researcher specialising in translational and interventional studies of rapid‑acting glutamatergic treatments for mood disorders. Her work centres on the therapeutic effects, safety profile and mechanistic correlates of repeated intravenous ketamine and esketamine in diverse depressive populations. Ning has been involved in randomised, active–placebo controlled trials assessing short‑term cognitive effects and anti‑suicidal activity of repeated esketamine in adolescents, and in comparative effectiveness studies examining anhedonia outcomes across melancholic vs non‑melancholic and bipolar vs unipolar depression.
Her contributions include investigation of functional outcomes (for example, social functioning) and mediating factors such as pain, as well as detailed safety and cognition assessments following repeated dosing. Collectively, these studies inform clinical decision‑making about patient selection, risk–benefit considerations and potential moderators of response to ketamine‑based interventions in both adult and adolescent psychiatric populations.